secwatch.observer — SEC 8-K summary
======================================

Issuer:     REPLIGEN CORP (RGEN)
CIK:        0000730272
Form:       8-K
Filed at:   2024-03-19T23:59:59+00:00
Accession:  0001193125-24-070768
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Repligen appoints Maggie A. Pax to Board of Directors, expanding to nine members
--------------------------------------------------------------------------------

- Pax elected to board effective March 18, 2024; board expands from eight to nine members.
- Pax brings 25+ years in life sciences, including Thermo Fisher VP Strategy and Innovation (2016-2020).
- Pax received initial option valued at $215,000 vesting over three years, plus pro-rata equity awards.
- Pax is independent under Nasdaq standards; no committee assignments yet.
- Pax also serves on boards of Alimera Sciences, Jellagen, and BioPorto U.S. subsidiary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/730272/000119312524070768/0001193125-24-070768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/730272/000119312524070768/d768236d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-070768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer